On 7 – 9 September 2022, ECDC organised with the Ministry of Health and the Georgian National Center for Disease Control and Public Health a consultative meeting with Georgian public health representatives and stakeholders.
The European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA) have issued a joint statement (link) providing updated public health considerations on the use of the newly authorised adapted COVID-19 vaccines to support the planning of the autumn and winter vaccination campaigns.
In order to maintain safe school environments and minimise student and staff absences, it is important to continue ensuring the prevention of the transmission of respiratory viruses such as influenza, respiratory syncytial virus (RSV), norovirus and SARS-CoV-2.
Following the joint statement from the European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA) on 11 July 2022, ECDC has released Preliminary public health considerations for COVID-19 vaccination strategies in the second half of 2022. ECDC, in collaboration with the World Health Organization (WHO) Regional Office for Europe, has also published Operational considerations for respiratory virus surveillance in Europe.